drugset / Trial / NCT01040793

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

NCT01040793

Phase 3 Completed 157 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.

Timeline

Start
2010-01
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled